Abstract No. 243 Associations Between Patterns of Neuroendocrine Liver Metastatic Burden and Outcomes After Liver-Directed Therapy, Systemic Chemotherapy, and Systemic Radiotherapy
Patients with metastatic neuroendocrine tumor (NET) have multiple options for liver-directed therapy (LDT) and systemic therapies. Post hoc analysis of NETTER-1 suggested that tumor size but not tumor burden predicted response and PFS after Peptide Receptor Radionuclide Therapy (PRRT), whereas a multicenter analysis of LDT found that tumor burden was predictive. We analyzed imaging datasets from two completed multicenter prospective clinical trials, ECOG-ACRIN E2211 and RETNET, and an institutional cohort of patients treated with PRRT to investigate whether morphologic subgroups of NET liver metastatic disease based on lesion size, lesion number and tumor burden might be more optimally treated with liver-directed therapy, systemic chemotherapy or systemic radiotherapy.
vigna
0
0
Patients with metastatic neuroendocrine tumor (NET) have multiple options for liver-directed therapy (LDT) and systemic therapies. Post hoc analysis of NETTER-1 suggested that tumor size but not tumor burden predicted response and PFS after Peptide Receptor Radionuclide Therapy (PRRT), whereas a multicenter analysis of LDT found that tumor burden was predictive. We analyzed imaging datasets from two completed multicenter prospective clinical trials, ECOG-ACRIN E2211 and RETNET, and an institutional cohort of patients treated with PRRT to investigate whether morphologic subgroups of NET liver metastatic disease based on lesion size, lesion number and tumor burden might be more optimally treated with liver-directed therapy, systemic chemotherapy or systemic radiotherapy.
